Progyny, Inc. (PGNY) P/E Ratio History
UndervaluedTrading at 39.7x vs 5Y avg 56.8x · 40th percentile · Below historical baseline · Data 2020–2026
Loading P/E history...
P/E Ratio Analysis
As of September 24, 2026, Progyny, Inc. (PGNY) trades at a price-to-earnings ratio of 39.7x, with a stock price of $25.83 and trailing twelve-month earnings per share of $0.96.
The current P/E is 30% below its 5-year average of 56.8x. Over the past five years, PGNY's P/E has ranged from a low of 22.1x to a high of 103.2x, placing the current valuation at the 40th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.7x, PGNY trades at a 68% premium to its sector peers. The sector includes 225 companies with P/E ratios ranging from 0.0x to 167.0x.
The PEG ratio of 5.93 (P/E divided by 14% EPS growth) suggests the stock may be expensive relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.
Relative to the broader market, PGNY commands a significant premium over the S&P 500 median P/E of 25.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our PGNY DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
PGNY Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
PGNY P/E vs Peers
Payer and Benefits Administration peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $6B | 55.7 | - | -4% | |
| $5B | 604.0 | - | +113%Best | |
| $1B | 38.9 | - | +104% | |
| $110B | 61.8 | - | -62% | |
| $71B | 12.1Lowest | - | +83% | |
| $337B | 28.1 | - | -15% | |
| $86B | 15.9 | 2.29Best | -2% | |
| $45B | 38.1 | - | -1% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
PGNY Historical P/E Data (2020–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q2 | - | $28.83 | $0.92 | 31.3x | -99% |
| FY2026 Q1 | - | $16.98 | $0.77 | 22.1x | -99% |
| FY2025 Q4 | Dec 31 2025 | $25.68 | $0.65 | 39.5x | -99% |
| FY2025 Q3 | - | $21.52 | $0.63 | 34.2x | -99% |
| FY2025 Q2 | Jun 30 2025 | $22.00 | $0.59 | 37.3x | -99% |
| FY2025 Q1 | Mar 31 2025 | $22.34 | $0.57 | 39.2x | -99% |
| FY2024 Q4 | - | $17.25 | $0.57 | 30.3x | -99% |
| FY2024 Q3 | Sep 30 2024 | $16.76 | $0.58 | 28.9x | -99% |
| FY2024 Q2 | Jun 30 2024 | $28.61 | $0.63 | 45.4x | -99% |
| FY2024 Q1 | Mar 31 2024 | $38.15 | $0.61 | 62.5x | -98% |
| FY2023 Q4 | Dec 31 2023 | $37.18 | $0.62 | 60.0x | -99% |
| FY2023 Q3 | Sep 30 2023 | $34.02 | $0.52 | 64.9x | -98% |
| FY2023 Q2 | Jun 30 2023 | $39.34 | $0.49 | 79.6x | -98% |
| FY2023 Q1 | Mar 31 2023 | $32.12 | $0.43 | 74.3x | -98% |
| FY2022 Q4 | Dec 31 2022 | $31.15 | $0.30 | 103.2x | -98% |
| FY2022 Q3 | Sep 30 2022 | $37.06 | $0.42 | 88.7x | -98% |
| FY2022 Q2 | - | $29.05 | $0.46 | 63.5x | -98% |
| FY2022 Q1 | - | $51.40 | $0.56 | 91.8x | -98% |
| FY2021 Q4 | Dec 31 2021 | $50.35 | $0.66 | 76.3x | -98% |
| FY2021 Q3 | - | $56.00 | $0.90 | 62.2x | -98% |
| FY2021 Q2 | Jun 30 2021 | $59.00 | $0.78 | 75.6x | -98% |
| FY2021 Q1 | Mar 31 2021 | $44.51 | $0.57 | 78.3x | -98% |
| FY2020 Q4 | - | $42.39 | $0.46 | 92.4x | -98% |
| FY2020 Q3 | Sep 30 2020 | $29.43 | $0.00 | 98100.0x | +2267% |
Average P/E for displayed period: 4145.1x
PGNY Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
6+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
PGNY — Frequently Asked Questions
Quick answers to the most common questions about buying PGNY stock.
What is PGNY's P/E ratio?
Progyny, Inc. (PGNY) trailing twelve-month P/E ratio is 39.7x, based on TTM diluted EPS of $0.96. The 5-year average P/E is 56.8x and the historical range spans 22.1x to 103.2x.
Is PGNY stock overvalued or undervalued?
PGNY trades at 39.7x P/E, below its 5-year average of 56.8x. At the 40th percentile of its historical range (22.1x–103.2x), the stock is priced at a discount to its own history.
Is PGNY stock expensive?
No, PGNY is not expensive on a historical basis. The current P/E of 39.7x is below the 5-year average of 56.8x and sits at the 40th percentile of its valuation range.
What is PGNY's historical P/E range?
Over the past 5 years, PGNY's P/E ratio has ranged from 22.1x to 103.2x, with a median of 62.2x and an average of 56.8x. The current P/E of 39.7x places the stock at the 40th percentile of this range. Full historical data spans 2020–2026.
How does PGNY's P/E compare to the S&P 500?
PGNY trades at 39.7x P/E versus the S&P 500 median of 25.3x. The 57% premium to the market typically reflects higher expected earnings growth or quality.
How does PGNY's valuation compare to Healthcare peers?
Progyny, Inc. P/E of 39.7x compares to the Healthcare sector median of 23.7x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is PGNY's PEG ratio?
PGNY PEG ratio is 5.93, based on a P/E of 39.7x and EPS growth of 14.0%. A PEG above 2.0 indicates a premium valuation relative to earnings growth — typically considered expensive.
What is PGNY's earnings yield?
PGNY earnings yield is 2.52%, the inverse of its 39.7x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.